Skip to search formSkip to main contentSkip to account menu

PF 04971729

Known as: PF-04971729, PF04971729 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Applicant : Mapi Pharma Ltd . , Ness Ziona ( IL ) s : R : 3 .
  • Spal
  • 2017
  • Corpus ID: 55897082
US 2014/O34301.0 A1 Nov. 20, 2014 pageS. BMS-AstraZeneca Dapagliflozin Diabetes Drug Falls Short; Pfizer's Related U.S… 
2015
2015
An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus
Introduction: Type 2 diabetes mellitus (T2DM) is a growing and serious global health problem. Pharmacological inhibition of the… 
Highly Cited
2013
Highly Cited
2013
Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects
The disposition of ertugliflozin (PF-04971729), an orally active selective inhibitor of the sodium-dependent glucose… 
2013
2013
Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes
  • 2013
  • Corpus ID: 62782968
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada (“Merck”), and Pfizer Inc. (NYSE:PFE) today… 
2012
2012
Metabolism and Excretion of the Anti-Diabetic Agent Ertugliflozin ( PF-04971729 ) in Healthy Male Subjects
Highly Cited
2011
Highly Cited
2011
Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.
Compound 4 (PF-04971729) belongs to a new class of potent and selective sodium-dependent glucose cotransporter 2 inhibitors… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)